Skip to main content
Top
Published in:

16-01-2024 | Voriconazole | Original Research Article

Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study

Authors: Khalid W. Taher, Razan Almofada, Sufyan Alomair, Ahmed A. Albassam, Abdullah Alsultan

Published in: Pediatric Drugs | Issue 2/2024

Login to get access

Abstract

Background and Objective

Voriconazole pharmacokinetics are highly variable in pediatric patients, and the optimal dosage has yet to be determined. The purpose of this study was to describe voriconazole pharmacokinetic and pharmacodynamic targets achieved and evaluate the efficacy and safety of voriconazole for critically ill pediatrics.

Methods

This is a single-center retrospective study conducted at a pediatric intensive care unit at a tertiary/quaternary hospital. Pediatrics admitted to the pediatric intensive care unit and who received voriconazole for a proven or suspected fungal infection with at least one measured trough concentration were included. The primary outcomes included the percentage of pediatric patients who achieved the pharmacokinetic and pharmacodynamic targets. Secondary outcomes included assessing the correlation between voriconazole trough concentrations and clinical/microbiological outcomes. All statistical analyses were performed using the R statistical software and Microsoft Excel. Multiple logistic regression was used to assess the predictors of both clinical and microbiologic cures. Multiple linear regression was used to determine significant factors associated with trough concentrations.

Results

A total of 129 voriconazole trough concentrations were measured from 71 participants at steady state after at least three doses of voriconazole. The mean (± standard deviation) of the first and second trough concentrations were 2.9 (4.2) and 2.3 (3.3) mg/L, respectively. Among the first trough concentrations, only 33.8% were within the therapeutic range (1–5 mg/L), 46.5% were below the therapeutic range, and 19.7% were above the therapeutic range. A clinical cure occurred in 78% of patients, while a microbiologic cure occurred in 80% of patients.

Conclusions

Voriconazole trough concentrations vary widely in critically ill pediatric patients and only a third of the patients achieved therapeutic concentrations with initial doses.
Literature
1.
go back to reference Ferreras-Antolín L, Sharland M, Warris A. Management of invasive fungal disease in neonates and children. Pediatr Infect Dis J. 2019;38(6S Suppl. 1):S2–6.CrossRefPubMedPubMedCentral Ferreras-Antolín L, Sharland M, Warris A. Management of invasive fungal disease in neonates and children. Pediatr Infect Dis J. 2019;38(6S Suppl. 1):S2–6.CrossRefPubMedPubMedCentral
2.
go back to reference Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-60.CrossRefPubMedPubMedCentral Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-60.CrossRefPubMedPubMedCentral
3.
go back to reference Hu L, Dai TT, Zou L, Li TM, Ding XS, Yin T. Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother. 2018;62(12):e00955-e1018.CrossRefPubMedPubMedCentral Hu L, Dai TT, Zou L, Li TM, Ding XS, Yin T. Therapeutic drug monitoring of voriconazole in children from a tertiary care center in China. Antimicrob Agents Chemother. 2018;62(12):e00955-e1018.CrossRefPubMedPubMedCentral
4.
go back to reference Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–71.CrossRefPubMed Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–71.CrossRefPubMed
5.
go back to reference Singh G, Pitoyo CW, Aditianingsih D, Rumende CM. Risk factors for early invasive fungal disease in critically ill patients. Indian J Crit Care Med. 2016;20(11):633–9.CrossRefPubMedPubMedCentral Singh G, Pitoyo CW, Aditianingsih D, Rumende CM. Risk factors for early invasive fungal disease in critically ill patients. Indian J Crit Care Med. 2016;20(11):633–9.CrossRefPubMedPubMedCentral
6.
go back to reference Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases: estimate precision. J Fungi (Basel). 2017;3(4):57.CrossRefPubMedPubMedCentral Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases: estimate precision. J Fungi (Basel). 2017;3(4):57.CrossRefPubMedPubMedCentral
7.
go back to reference Zhang MK, Rao ZG, Ma T, Tang M, Xu TQ, He XX, et al. Appropriate empirical antifungal therapy is associated with a reduced mortality rate in intensive care unit patients with invasive fungal infection: a real-world retrospective study based on the MIMIC-IV database. Front Med (Lausanne). 2022;9: 952611.CrossRefPubMedPubMedCentral Zhang MK, Rao ZG, Ma T, Tang M, Xu TQ, He XX, et al. Appropriate empirical antifungal therapy is associated with a reduced mortality rate in intensive care unit patients with invasive fungal infection: a real-world retrospective study based on the MIMIC-IV database. Front Med (Lausanne). 2022;9: 952611.CrossRefPubMedPubMedCentral
8.
go back to reference Valle-T-Figueras JM, Renedo Miró B, Benítez Carabante MI, Díaz-de-Heredia C, Vima Bofarull J, Mendoza-Palomar N, et al. Voriconazole use in children: therapeutic drug monitoring and control of inflammation as key points for optimal treatment. J Fungi (Basel). 2021;7(6):456.CrossRefPubMedPubMedCentral Valle-T-Figueras JM, Renedo Miró B, Benítez Carabante MI, Díaz-de-Heredia C, Vima Bofarull J, Mendoza-Palomar N, et al. Voriconazole use in children: therapeutic drug monitoring and control of inflammation as key points for optimal treatment. J Fungi (Basel). 2021;7(6):456.CrossRefPubMedPubMedCentral
9.
go back to reference Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, Johnson JA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy. 2014;34(7):703–18.CrossRefPubMed Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, Johnson JA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy. 2014;34(7):703–18.CrossRefPubMed
10.
go back to reference John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15(11):881–95.CrossRefPubMed John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15(11):881–95.CrossRefPubMed
11.
go back to reference Duehlmeyer S, Klockau C, Yu D, Rouch J. Characterization of therapeutic drug monitoring practices of voriconazole and posaconazole at a pediatric hospital. J Pediatr Pharmacol Ther. 2021;26(1):26–32.PubMedPubMedCentral Duehlmeyer S, Klockau C, Yu D, Rouch J. Characterization of therapeutic drug monitoring practices of voriconazole and posaconazole at a pediatric hospital. J Pediatr Pharmacol Ther. 2021;26(1):26–32.PubMedPubMedCentral
12.
go back to reference Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–85.CrossRefPubMedPubMedCentral Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–85.CrossRefPubMedPubMedCentral
13.
go back to reference Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, Peloquin CA. Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther. 2015;20(1):17–23.PubMedPubMedCentral Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, Peloquin CA. Voriconazole monitoring in children with invasive fungal infections. J Pediatr Pharmacol Ther. 2015;20(1):17–23.PubMedPubMedCentral
14.
go back to reference Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927–33.CrossRefPubMed Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect. 2010;16(7):927–33.CrossRefPubMed
15.
go back to reference Boast A, Curtis N, Cranswick N, Gwee A. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother. 2016;71(7):2031–6.CrossRefPubMed Boast A, Curtis N, Cranswick N, Gwee A. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother. 2016;71(7):2031–6.CrossRefPubMed
16.
go back to reference Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit. 2012;34(1):77–84.CrossRefPubMed Chen J, Chan C, Colantonio D, Seto W. Therapeutic drug monitoring of voriconazole in children. Ther Drug Monit. 2012;34(1):77–84.CrossRefPubMed
17.
go back to reference Lin XB, Huang F, Tong L, Xia YZ, Wu JJ, Li J, et al. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: a prospective study in the intensive care unit. Int J Infect Dis. 2020;93:345–52.CrossRefPubMed Lin XB, Huang F, Tong L, Xia YZ, Wu JJ, Li J, et al. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: a prospective study in the intensive care unit. Int J Infect Dis. 2020;93:345–52.CrossRefPubMed
18.
go back to reference Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 2012;67(11):2717–24.CrossRefPubMed Pieper S, Kolve H, Gumbinger HG, Goletz G, Würthwein G, Groll AH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 2012;67(11):2717–24.CrossRefPubMed
19.
go back to reference Mori M, Fukushima K, Miharu M, Goto H, Yoshida M, Shoji S. A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients. J Infect Chemother. 2013;19(1):174–9.CrossRefPubMed Mori M, Fukushima K, Miharu M, Goto H, Yoshida M, Shoji S. A retrospective analysis of voriconazole pharmacokinetics in Japanese pediatric and adolescent patients. J Infect Chemother. 2013;19(1):174–9.CrossRefPubMed
20.
go back to reference Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monit. 2011;33(4):464–6.CrossRefPubMed Gerin M, Mahlaoui N, Elie C, Lanternier F, Bougnoux ME, Blanche S, et al. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency. Ther Drug Monit. 2011;33(4):464–6.CrossRefPubMed
21.
go back to reference Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23.CrossRefPubMedPubMedCentral Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23.CrossRefPubMedPubMedCentral
22.
go back to reference Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine. Antibiotics (Basel). 2021;10(10):1182.CrossRefPubMedPubMedCentral Gijsen M, Vlasselaers D, Spriet I, Allegaert K. Pharmacokinetics of antibiotics in pediatric intensive care: fostering variability to attain precision medicine. Antibiotics (Basel). 2021;10(10):1182.CrossRefPubMedPubMedCentral
23.
go back to reference Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93.
26.
go back to reference Bury D, Tissing WJE, Muilwijk EW, Wolfs TFW, Brüggemann RJ. Clinical pharmacokinetics of triazoles in pediatric patients. Clin Pharmacokinet. 2021;60(9):1103–47.CrossRefPubMedPubMedCentral Bury D, Tissing WJE, Muilwijk EW, Wolfs TFW, Brüggemann RJ. Clinical pharmacokinetics of triazoles in pediatric patients. Clin Pharmacokinet. 2021;60(9):1103–47.CrossRefPubMedPubMedCentral
27.
go back to reference Shi C, Xiao Y, Mao Y, Wu J, Lin N. Voriconazole: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2019;58(6):687–703.CrossRefPubMed Shi C, Xiao Y, Mao Y, Wu J, Lin N. Voriconazole: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2019;58(6):687–703.CrossRefPubMed
28.
go back to reference van den Born DA, Märtson AG, Veringa A, Punt NC, van der Werf TS, Alffenaar JC, et al. Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model. Int J Antimicrob Agents. 2023;61(4): 106750.CrossRefPubMed van den Born DA, Märtson AG, Veringa A, Punt NC, van der Werf TS, Alffenaar JC, et al. Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model. Int J Antimicrob Agents. 2023;61(4): 106750.CrossRefPubMed
29.
go back to reference Li X, Lai F, Jiang Z, Li M, Chen Z, Cheng J, et al. Effects of inflammation on voriconazole levels: a systematic review. Br J Clin Pharmacol. 2022;88(12):5166–82.CrossRefPubMed Li X, Lai F, Jiang Z, Li M, Chen Z, Cheng J, et al. Effects of inflammation on voriconazole levels: a systematic review. Br J Clin Pharmacol. 2022;88(12):5166–82.CrossRefPubMed
30.
go back to reference Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76.CrossRefPubMed Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76.CrossRefPubMed
31.
go back to reference Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57(1):235–40.CrossRefPubMedPubMedCentral Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57(1):235–40.CrossRefPubMedPubMedCentral
32.
go back to reference Kang HM, Lee HJ, Cho EY, Yu KS, Lee H, Lee JW, et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr Hematol Oncol. 2015;32(8):557–67.CrossRefPubMed Kang HM, Lee HJ, Cho EY, Yu KS, Lee H, Lee JW, et al. The clinical significance of voriconazole therapeutic drug monitoring in children with invasive fungal infections. Pediatr Hematol Oncol. 2015;32(8):557–67.CrossRefPubMed
33.
go back to reference Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, Henriet S, van der Sluis IM, Hanff LM, et al. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Med Mycol. 2019;57(8):937–43.CrossRefPubMed Lempers VJ, Meuwese E, Mavinkurve-Groothuis AM, Henriet S, van der Sluis IM, Hanff LM, et al. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients. Med Mycol. 2019;57(8):937–43.CrossRefPubMed
34.
go back to reference Hanai Y, Hamada Y, Kimura T, Matsumoto K, Takahashi Y, Fujii S, et al. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: a systematic review and meta-analysis. J Infect Chemother. 2021;27(2):151–60.CrossRefPubMed Hanai Y, Hamada Y, Kimura T, Matsumoto K, Takahashi Y, Fujii S, et al. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: a systematic review and meta-analysis. J Infect Chemother. 2021;27(2):151–60.CrossRefPubMed
35.
go back to reference Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.CrossRefPubMed Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–11.CrossRefPubMed
36.
go back to reference Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013;60(1):82–7.CrossRefPubMed Choi SH, Lee SY, Hwang JY, Lee SH, Yoo KH, Sung KW, et al. Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. Pediatr Blood Cancer. 2013;60(1):82–7.CrossRefPubMed
37.
go back to reference Shen K, Gu Y, Wang Y, Lu Y, Ni Y, Zhong H, et al. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. Ther Adv Drug Saf. 2022;13:20420986221127504.CrossRefPubMedPubMedCentral Shen K, Gu Y, Wang Y, Lu Y, Ni Y, Zhong H, et al. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases. Ther Adv Drug Saf. 2022;13:20420986221127504.CrossRefPubMedPubMedCentral
38.
go back to reference Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient: concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.CrossRefPubMed Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient: concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.CrossRefPubMed
40.
go back to reference Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Brüggemann RJ, Jelliffe RW, et al. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother. 2013;57(4):1888–94.CrossRefPubMedPubMedCentral Hope WW, Vanguilder M, Donnelly JP, Blijlevens NM, Brüggemann RJ, Jelliffe RW, et al. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob Agents Chemother. 2013;57(4):1888–94.CrossRefPubMedPubMedCentral
41.
go back to reference Hope W, Johnstone G, Cicconi S, Felton T, Goodwin J, Whalley S, et al. Software for dosage individualization of voriconazole: a prospective clinical study. Antimicrob Agents Chemother. 2019;63(4):e02353-e2418.CrossRefPubMedPubMedCentral Hope W, Johnstone G, Cicconi S, Felton T, Goodwin J, Whalley S, et al. Software for dosage individualization of voriconazole: a prospective clinical study. Antimicrob Agents Chemother. 2019;63(4):e02353-e2418.CrossRefPubMedPubMedCentral
Metadata
Title
Therapeutic Drug Monitoring of Voriconazole in Critically Ill Pediatric Patients: A Single-Center Retrospective Study
Authors
Khalid W. Taher
Razan Almofada
Sufyan Alomair
Ahmed A. Albassam
Abdullah Alsultan
Publication date
16-01-2024
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 2/2024
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-023-00616-4

Other articles of this Issue 2/2024

Pediatric Drugs 2/2024 Go to the issue